BioNTech SE (BNTX)
收市後：
| 前收市價 | 89.95 |
| 開市 | 90.81 |
| 買盤 | 92.15 x 200 |
| 賣出價 | 92.34 x 100 |
| 今日波幅 | 90.68 - 92.40 |
| 52 週波幅 | 85.21 - 125.83 |
| 成交量 | |
| 平均成交量 | 587,959 |
| 市值 | 22.229B |
| Beta 值 (5 年，每月) | 0.23 |
| 市盈率 (最近 12 個月) | 22.50 |
| 每股盈利 (最近 12 個月) | 4.10 |
| 業績公佈日 | 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2022年6月02日 |
| 1 年預測目標價 | 118.16 |
ZacksBioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
